Table of Contents
- Trial overview
- Study design and treatment groups
- Who participated
- What the trial measured
- What the results were meant to show
Trial overview
The source data include one completed clinical trial of Human Hepatitis B Immunoglobulin in people with chronic hepatitis B.[1] It was a Phase 2 interventional study, which means researchers gave a study treatment and then measured the response.[1] The trial enrolled 20 people.[1]
Study design and treatment groups
The study aimed to evaluate the effect of 12 weeks of treatment with hepatitis B immunoglobulins in two different cohorts, or groups, of patients with chronic hepatitis B.[1] The interventions listed were Hepatect CP 50 I.E./ml Infusionslösung given by IV infusion and Zutectra 500 IU solution for injection in a pre-filled syringe given by subcutaneous injection.[1] IV infusion means medicine is given into a vein, and subcutaneous means under the skin.
Who participated
The trial population was people with chronic hepatitis B.[1] The source data do not give more detail about age, sex, previous treatment, or other entry rules, so those details cannot be confirmed from the available record.
What the trial measured
The main outcome was HBsAg negativity at week 12 of antiviral therapy.[1] HBsAg stands for hepatitis B surface antigen, a blood marker used in hepatitis B studies.[1] A negative result means the marker was not found in the blood at that time point.
What the results were meant to show
This study was designed to see whether Human Hepatitis B Immunoglobulin could help more people reach HBsAg negativity during antiviral therapy.[1] Because the trial is listed as completed, the main focus of the record is the study plan and endpoint rather than a published outcome summary.[1]
